


# BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 05.02.2025

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Dear Sir / Madam,  
Scrip Code: 531752 Security 10: BIOGEN

Sub. : Integrated Filing (Financial) for the quarter and Nine-month ended 31<sup>st</sup> December, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, please find attached herewith the Integrated Filing (Financial) for the Quarter and Nine-month ended 31st December, 2024.:


A	Financial Results	Attached as Annexure-1
B	Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	Not Applicable
C	Format for disclosing outstanding default on loans and debt securities	Not Applicable
D	Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)	Not Applicable for this quarter
E	Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (Applicable only for annual filing i.e., 4th quarter)	Not Applicable for this quarter

Kindly take the same on your record.

Thanking you,

Yours Faithfully,  
FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED

HARSHAD RATHOD  
DIRECTOR



Registered Office Address: Shop No. 8, First Floor, Maker's - 1 Building, Jawahar Road, Rajkot-360001  
E mail [biogenpharmachem@gmail.com](mailto:biogenpharmachem@gmail.com)

## Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

### Statement of Unaudited Financial Results for the Quarter Ended December 31, 2024

(Rs. In lacs)							
Sl No.	Particulars	Quarter Ended 31 Dec'2024	Quarter Ended 30 Sept'2024	Quarter Ended 31 Dec'2023	Nine Monts Ended 31 Dec'2024	Nine Monts Ended 31 Dec'2023	Year Ended 31 Mar 2024
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>						
(a)	Revenue from Operations	-	-	-	-	-	-
(b)	Other Income	22.76	(65.05)	9.24	(51.39)	160.22	238.15
	<b>Total Income from Operations (Net)</b>	<b>22.76</b>	<b>(65.05)</b>	<b>9.24</b>	<b>(51.39)</b>	<b>160.22</b>	<b>238.15</b>
<b>2</b>	<b>Expenses</b>						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Purchase of stock in trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	5.05	1.03	0.94	7.46	6.94	8.40
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	49.20	33.65	2.07	88.20	34.35	36.68
	<b>Total Expenses</b>	<b>54.25</b>	<b>34.68</b>	<b>3.01</b>	<b>95.66</b>	<b>41.29</b>	<b>45.08</b>
<b>3</b>	<b>Profit / (Loss) from operations before exceptional items and Tax (1-2)</b>	<b>(31.49)</b>	<b>(99.73)</b>	<b>6.23</b>	<b>(147.05)</b>	<b>118.93</b>	<b>193.07</b>
<b>4</b>	<b>Exceptional Items</b>						
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(31.49)</b>	<b>(99.73)</b>	<b>6.23</b>	<b>(147.05)</b>	<b>118.93</b>	<b>193.07</b>
<b>6</b>	<b>Tax Expense</b>	-	-	-	-	-	-
<b>7</b>	<b>Profit / (Loss) after tax (5 - 6)</b>	<b>(31.49)</b>	<b>(99.73)</b>	<b>6.23</b>	<b>(147.05)</b>	<b>118.93</b>	<b>193.07</b>
<b>8</b>	<b>Other comprehensive income (Net of Tax)</b>						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
<b>9</b>	<b>Total comprehensive income (7 ± 8)</b>	<b>(31.49)</b>	<b>(99.73)</b>	<b>6.23</b>	<b>(147.05)</b>	<b>118.93</b>	<b>193.07</b>
<b>10</b>	<b>Paid-up equity share capital (Face Value of Rs.1/- each)</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>
<b>11</b>	<b>Other Equity</b>						(873.99)
<b>12</b>	<b>Earnings Per Share (before extraordinary items) (of Rs. 1/- each) (not annualised):</b>						
	(a) Basic	(0.00)	(0.02)	0.00	(0.02)	0.02	0.03
	(b) Diluted	(0.00)	(0.02)	0.00	(0.02)	0.02	0.03

**Notes:**

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 05, 2025. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Rajkot

Date : 05th February, 2025





# RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.  
Tel.: 9820501848, Email : rishisekhri@gmail.com

## Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors of  
**Biogen Pharmachem Industries Limited**

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Biogen Pharmachem Industries Limited** ("the Company"), for the Quarter ended on December 31, 2024 and year to date result for the period from 01 April, 2024 to 31 December, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,  
Chartered Accountants  
FRN: 128216W

CA RISHI SEKHRI  
Partner  
NO. 126656



Place:- Mumbai  
Date:- 5.2.2025  
UDIN:25126656NKEZTW6585